Nathaniel O’Connell

Mar 27, 2024 | jamanetwork.com | John Devin Peipert |Edward H. Ip |Nathaniel O’Connell |Ruth Carlos

Key PointsQuestion  Are direct reports from patients about their treatment’s adverse effects associated with early treatment discontinuation?

Jun 1, 2023 | jacc.org | Moriah P. Bellissimo |Kerryn Reding |Nathaniel O’Connell |Ralph B. D’Agostino

JACC Journals › JACC: CardioOnc › Archives › Vol. 5 No. 3 IntroductionCancer survivors who received anthracycline-based chemotherapy (ANTH) are at increased risk of cancer therapy–related cardiovascular dysfunction and reduced left ventricular ejection fraction (LVEF), contributing to a heightened risk of developing heart failure (HF).